RayzeBio, Inc. Common Stock
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kenneth Song
- Full Time Employees
- 88
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- DE United States of America
- IPO Date
- Sep 15, 2023
- CIK
- 0001825367
- Similar Companies
- Business
- RayzeBio, Inc., now operating as a subsidiary of Bristol Myers Squibb following its acquisition for approximately $4.1 billion in early 2024, is dedicated to advancing radiopharmaceutical therapeutics for cancer treatment. The company's primary focus involves developing targeted treatments utilizing alpha-emitting radioisotopes, particularly Actinium-225 (Ac225), which aims for potent and precise tumor destruction. Its lead therapeutic candidate, RYZ101, is an Actinium-225-based agent designed to target somatostatin receptor 2 (SSTR2), which is frequently overexpressed in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and extensive-stage small cell lung cancer (ES-SCLC). RYZ101 is currently undergoing a pivotal Phase 3 clinical trial for GEP-NETs in patients whose disease has progressed after prior lutetium-177-based therapies, with initial Phase 1b findings demonstrating encouraging efficacy and tolerability. Additionally, a Phase 1b study is evaluating RYZ101 for the first-line treatment of ES-SCLC in combination with standard care. It should be noted that new patient enrollment for the Phase 3 GEP-NETs study was temporarily paused in mid-2024 due to Actinium-225 supply limitations, with re-enrollment anticipated for the third quarter of 2024. The company's robust pipeline also includes RYZ801, a proprietary peptide targeting GPC3 for Actinium-225 delivery in hepatocellular carcinoma (HCC), currently in IND-enabling studies. Other candidates in development target carbonic anhydrase 9 (CA9) for renal cell carcinoma, and the pipeline expanded in mid-2025 to include therapies for prostate cancer through a significant licensing agreement. To support its innovative therapies, RayzeBio is finalizing a state-of-the-art manufacturing facility in Indianapolis, Indiana, with drug production expected to commence in the first half of 2024. Established in 2020, the company maintains its headquarters in San Diego, California.
Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform
Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
IPO watch 2024: Which new stocks will hit the market?
Cramer names biopharma companies to watch as industry mergers start to pile up
RAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZB
Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target
Yes Virginia, There Is a Santa Claus Rally
Bristol Myers Squibb Buys RayzeBio, Its Second Multibillion-Dollar Deal in Days
Midday Movers: Intel's Israel Deal, Bristol-Myers Squibb Buys RayzeBio
Bristol Myers Squibb goes back to the acquisition well with $4.1B purchase of RayzeBio
Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%
Shareholder Alert: Ademi LLP investigates whether RayzeBio, Inc. has obtained a Fair Price in its transaction with Bristol Myers
Why Is RayzeBio (RYZB) Stock Up 100% Today?
RYZB Stock Alert: Halper Sadeh LLC Is Investigating RayzeBio, Inc.
Bristol Myers to buy RayzeBio for about $4.1B
Nano Dimension Buys Stratasys, Bristol Myers's Shopping Spree, Apple Gets a ‘No'
RayzeBio: New IPO With Good Data And Solid Premise
Bristol Myers strikes $4.1 bln RayzeBio deal for targeted cancer therapies
Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion